You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Acute otitis media (AOM)

Demonstrated efficacy against first episodes of AOM* 1

Vaccine efficacy of SYNFLORIX in the ATP cohort

Demonstrated efficacy against first episodes of AOM

Adapted from Product Monograph1

* Double-blind study in healthy infants aged 6 to 16 weeks who were randomized to SYNFLORIX or hepatitis B control vaccine at 2, 4 and 6 months of age followed respectively by either SYNFLORIX or hepatitis A control vaccine at 15 to 18 months of age. The ATP cohort (n=5989) was defined as the group of participants immunized with at least the three-dose primary series.


  1. Synflorix Product Monograph. GlaxoSmithKline Inc. August 31, 2018.